

Statement by the National Investing Bodies on Human Embryology

On behalf of the Church of England National Investing Bodies (NIBs), the Ethical Investment Advisory Group (EIAG) has completed a review of the existing ethical investment policy on **Human Embryonic Cloning (2008)**.

The review was supported by the Church of England's Mission and Public Affairs (MPA) division and covered issues such as, but not restricted to, the status and dignity of the human embryo, germline gene editing, pre-implantation genetic diagnosis, non-invasive pre-natal testing and the use of aborted embryonic or foetal material in research. It noted the potential opportunities and associated ethical concerns arising from developments in science and policy in each of these areas.

Following the Review the EIAG and the NIBs have agreed that, due to the increased pace of developments and the complex and nuanced nature of the issues, it is not possible to develop specific and durable ethical investment policy at this time. Instead, the NIBs will, as best and sensitively as possible, have regard to the position statements issued by MPA when considering investments in, and undertaking engagement with, companies involved in new medical technologies.